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Abstract
Background: The Oncomine™ database is an online collection of microarrays from various
sources, usually cancer-related, and contains many "multi-arrays" (collections of analyzed
microarrays, in a single study). As there are often many hundreds of tumour samples/microarrays
within a single multi-array results from coexpressed genes can be analyzed, and are fully searchable.
This gives a potentially significant list of coexpressed genes, which is important to define pathways
in which the gene of interest is involved. However, to increase the likelihood of revealing truly
significant coexpressed genes we have analyzed their frequency of occurrence over multiple studies
(meta-analysis), greatly increasing the significance of results compared to those of a single study.
Results: We have used the DEAD-box proteins p68(Ddx5) and p72(Ddx17) as models for this
coexpression frequency analysis as there are defined functions for these proteins in splicing and
transcription (known functions which we could use as a basis for quality control). Furthermore, as
these proteins are highly similar, interact together, and may be to some degree functionally
redundant, we then analyzed the overlap between coexpressed genes of p68 and p72. This final
analysis gave us a highly significant list of coexpressed genes, clustering mainly in splicing and
transcription (recapitulating their published roles), but also revealing new pathways such as
cytoskeleton remodelling and protein folding. We have further tested a predicted pathway partner,
RNA helicase A(Dhx9) in a reciprocal meta-analysis that identified p68 and p72 as being
coexpressed, and further show a direct interaction of Dhx9 with p68 and p72, attesting to the
predictive nature of this technique.
Conclusion: In summary we have extended the capabilities of Oncomine™ by analyzing the
frequency of coexpressed genes over multiple studies, and furthermore assessing the overlap with
a known pathway partner (in this case p68 with p72). We have shown our predictions corroborate
previously published studies on p68 and p72, and that novel predictions can be easily tested. These
techniques are widely applicable and should increase the quality of data from future meta-analysis
studies.
Background
Recently there have been attempts to correlate published
microarrays, using software that can analyze many thou-
sands of microarrays at one time. One such program is
called Oncomine™ [1], where each study within Oncom-
ine™ is in essence a collection of individual microarrays
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from many patient samples[2]. These "multi-arrays" usu-
ally utilise either normal or tumour biopsy samples (or
compare both together), from various tissue sources.
One function of Oncomine™ is a search tool where the
user's chosen gene is correlated in expression, within
multi-arrays, with other genes in the array (both high and
low expression, over all the samples in the multi-array).
For example searching p72 (DDX17) gives several correla-
tions in many multi-arrays. Focusing within the study
Whitney_normal there is a high correlation with expres-
sion of fibrillarin, over the 147 blood samples tested (Fig-
ure 1A). In samples where p72 expression was
diminished, so was fibrillarin, and conversely when p72
expression was high, so is that of fibrillarin. This result is
Oncomine studies utilised and methodology of analysis Figure 1
Oncomine studies utilised and methodology of analysis. (A) Screenshot example of Oncomine™ output of p72 
(DDX17) coexpression with fibrillarin (FBL) in one multi-array study, covering 147 samples. p72 is X-axis and fibrillarin is Y-axis. 
(B) Procedure employed for meta-analysis of 19 different multi-arrays after searching for either p68 or p72, extracting the top 
400 coexpressed genes from each multi-array, and comparing for frequency of repetition. (C) Chosen multi-arrays to be stud-
ied for both p68 and p72.
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From: Whitney_normal [blood]
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Top 400
Expression
Correlations
Frequency:
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p68 and p72
Meta Analysis - Procedure
C.
p68 multi-arrays p72 multi-arrays
10/19 overlap
Whitney_Normal (147) Whitney_Normal (147)
Shyamsundar_Normal (123) Shai_Brain (41)
Hsiao_Normal (62) Nutt_Brain (50)
Ramaswamy_Multi-cancer_2 (76) Ramaswamy_Multi-cancer_2 (76)
Ramaswamy_Multi-cancer (288) Ramaswamy_Multi-cancer (288)
Higgins_Renal (44) Boer_Renal (180)
Vasselli_Renal (58) Yu_Prostate (112)
Lacayo_Leukemia (87) Lacayo_Leukemia (87)
Bullinger_Leukemia (119) Fine_Leukemia (42)
Cario_Leukemia (51) Cario_Leukemia (51)
Dhanasekaran_Prostate (101) Dhanasekaran_Prostate (101)
Lapointe_Prostate (112) Lapointe_Prostate (112)
Garber_Lung (73) Singh_Prostate (102)
Gruvberger_Breast (58) vandeVijver_Breast (295)
Sperger_Others (74) Garber_Lung (73)
Chen_Liver (197) Lu_Ovarian (50)
Schaner_Ovarian (44) Haqq_Melanoma (37)
Iacobuzio-Donahue_Pancreas_2 (31) Chen_Liver (197)
Lossos_Lymphoma (35) Lossos_Lymphoma (35)
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made more significant given that p72 and fibrillarin have
previously been shown to interact together[3].
Correlations like this can show if proteins may be in the
same pathway (e.g. both coregulated together, or one
directly affecting the other), although it cannot show
more than association. In an attempt to further increase
the stringency of Oncomine™ to elude to these pathways
we chose to test the DEAD-box proteins p68 and p72
because they are highly similar proteins that interact
together and have been shown to be involved in defined
cellular functions including splicing and transcription,
which can then be used as a quality control measure of
this technique [4-10]. Also as p68 and p72 are so similar
there is the possibility that they may to some extent be
functionally redundant.
In total this means that we can perform a meta-analysis of
p68 coexpressed genes independent to that of p72, then
compare the results for overlap (Figure 1B). If the gene
lists were to give a significant overlap then this would act
to support the notion that the technique is highly selec-
tive. Our results reveal that, not only does this technique
corroborate previously published data on p68 and p72, it
also generates testable predictions of novel pathway part-
ners of p68 and p72.
Results
Overlapping coexpressed genes of p68 and p72
Multi-arrays chosen for meta-analysis had many individ-
ual samples/microarrays, indicating that a good correla-
tion coefficient given by Oncomine™ is already highly
significant. Figure 1C indicates the chosen multi-array
studies for p68 and p72. Note that there is almost a 50%
overlap of studies chosen.
Meta-analysis results, with frequency of 3 or more, for p68
yielded a higher volume of hits than for p72 (see Addi-
tional file 1). Both of these lists were compared for com-
mon genes and the common list was further assessed for
ontology and full gene names (Table 1). Remarkably, we
observed a large number of overlapping genes, indicative
of the stringency employed in this technique.
Even when the stringency was further augmented by
increasing the p68 frequency cut-off to 4 or more multi-
arrays (21% and above overlap within p68 multi-arrays),
this lost almost 300 p68 hits, but only reduced the
number of overlapping genes with p72 from 90 to 70 (Fig-
ure 2A). The highest frequency of overlap of p68 and p72
occurred in splicing, consistent with previous reports of
their role in this process. Further validation of this tech-
nique was observed by the reciprocal gene hits of p68 and
Analysis of overlap of p68 and p72 coexpressed genes Figure 2
Analysis of overlap of p68 and p72 coexpressed genes. (A) Venn diagram of overlap of frequency = 3 or more, genes 
from p68 and p72 analysis, and when p68 frequency is increased to 4 or more. (B) Ontology pie-chart of p68/p72 overlapping 
frequency = 3 or more, gene products.BMC Genomics 2007, 8:419 http://www.biomedcentral.com/1471-2164/8/419
Page 4 of 11
(page number not for citation purposes)
Table 1: Frequency overlap between p68 and p72 coexpressed genes.
Gene p68 % p72 % Function Gene Name
TIA1 26% 16% Splicing cytotoxic granule-associated RNA-binding protein
SFRS5 37% 21% Splicing splicing factor, arginine/serine-rich, 5
SFPQ 42% 47% Splicing splicing factor proline/glutamine rich (polypyrimidine tract binding protein 
associated)
SF1 37% 26% Splicing splicing factor 1
MBNL1 53% 32% Alternative Splicing muscleblind-like protein(Triplet-expansion RNA-binding protein)
HNRPH1 47% 32% Splicing heterogeneous nuclear ribonucleoprotein H (hnRNP H)
CROP 21% 37% SR Protein -Splicing? cisplatin resistance-associated overexpressed protein (LUC7A)
CPSF2 42% 21% Splicing cleavage and polyadenylation specificity factor
C6orf111 32% 32% Splicing splicing factor, arginine/serine-rich 130
FLJ12529 21% 16% Splicing pre-mRNA cleavage factor I, 59 kDa subunit
DDX5 100% 26% Splicing/Transcription p68 DEAD-box RNA helicase
DDX17 26% 100% Splicing/Transcription p72 DEAD-box RNA helicase
PAPOLA 26% 21% Transcription/Splicing poly(A) polymerase alpha
ILF3 26% 21% Transcription/Splicing NFAR1/NF-90/subunit of NFAT transcription factor
PNN 16% 21% Transcription/Splicing pinin(DRS)
XBP1 26% 21% Transcription/ER-alpha pathway X-box binding protein 1
THRAP2 32% 21% Transcription? thyroid hormone receptor associated protein 2
RORA 26% 26% Transcription RAR-related orphan receptor alpha
PTMA 21% 16% Transcription prothymosin, alpha (gene sequence 28)
DHX9 47% 32% Transcription RNA Helicase A/DEAH (Asp-Glu-Ala-His) box polypeptide 9
BMI1 21% 16% Transcription Silencing B lymphoma Mo-MLV insertion region (mouse) [Polycomb complex protein 
BMI-1]
SMARCA2 16% 21% Transcription SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 2
HIF1A 16% 16% Transcription hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription 
factor)
MAP3K7IP2 26% 21% Signal Transduction/Transcription mitogen-activated protein kinase kinase kinase 7 interacting protein 2 (TAB2)
PRKAR1A 47% 32% Signal Transduction protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific 
extinguisher 1)
PIK3R1 21% 21% Signal Transduction phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha)
HIPK2 32% 16% Signal Transduction/Apoptosis homeodomain interacting protein kinase 2
DNAJC3 21% 16% Signal Transduction DnaJ homolog subfamily C member 3 (Interferon-induced, double-stranded 
RNA-activated protein kinase inhibitor)
CSNK1A1 32% 21% Signal Transduction casein kinase 1, alpha 1
GNAS 21% 21% Receptor-Stimulated G-Protein guanine nucleotide binding protein (G protein), alpha stimulating activity 
polypeptide 1
ABI2 26% 21% Cytoskeleton Abl-interactor 2 (Abelson interactor 2)
ARPC3 21% 26% Cytoskeleton actin related protein 2/3 complex, subunit 3, 21kDa (p21-ARC)
FNBP4 26% 21% Cytoskeleton? formin binding protein 4
WASPIP 16% 16% Cytoskeleton Wiskott-Aldrich syndrome protein interacting protein
UTRN 16% 21% Cytoskeleton utrophin (homologous to dystrophin)
RAP2A 16% 16% Cytoskeleton? RAP2A, member of RAS oncogene family
NEDD5 16% 21% Cytoskeleton/cell-cycle? septin 2 (GTP-binding protein family)
ACTB 16% 26% Cytoskeleton beta actin
MAPRE2 16% 16% Cytoskeleton microtubule-associated protein, RP/EB family, member 2
SDCBP 21% 21% Scaffold Protein syndecan binding protein (syntenin)
HNRPU 42% 32% Nuclear Matrix Attachment heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A)
XPO1 26% 21% Nuclear Export exportin 1 (CRM1 homolog, yeast)
TNPO1 26% 32% Nuclear Import transportin 1
NUP133 26% 16% Nuclear Pore nuclear pore complex protein Nup133
ZFR 26% 21% Nuclear RNA binding zinc finger RNA binding protein
RAB5A 16% 16% Endocytosis RAB5A, member RAS oncogene family
RAB6A 68% 16% Golgi-ER trafficking RAB6A, member RAS oncogene family
GDI2 26% 26% ER-golgi?(Interacts Rab6, above) rab GDP-dissociation inhibitor, beta
EDEM1 21% 32% Calnexin cycle/protein folding ER degradation enhancer, mannosidase alpha-like 1
RAB14 32% 26% Golgi-endosome trafficking RAB14, member RAS oncogene family
PLEKHB2 26% 16% post-golgi vesicle protein pleckstrin homology domain containing, family B (evectins) member 2
TMP21 37% 37% Trafficking transmembrane trafficking protein
TRAM1 26% 16% Protein Translocation translocation associated membrane protein 1BMC Genomics 2007, 8:419 http://www.biomedcentral.com/1471-2164/8/419
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SLC38A2 21% 21% Amino acid transport Solute carrier family 38, member 2
SLC25A5 26% 25% ADP/ATP carrier protein Solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 5
CGI-109 37% 16% Protein transport? hypothetical protein
USP9X 21% 16% Ubiquitin ubiquitin specific protease 9, X chromosome (Drosophila fat facets related)
UBE2J1 21% 32% Ubiquitin ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast)
UBE3A 16% 21% Ubiquitin ubiquitin protein ligase E3A
BIRC6 16% 21% Ubiquitin ligase/Anti-apoptosis baculoviral IAP repeat-containing 6 (apollon)
BIRC2 32% 21% Apoptosis-resistance baculoviral IAP repeat-containing 2
PSMA2 21% 21% Proteasome proteasome (prosome, macropain) subunit, alpha type, 2
PIAS1 26% 21% E3-SUMO Ligase protein inhibitor of activated STAT, 1 (DEAD/H box-binding protein 1)
MAK3 21% 16% N-acetyltransferase Mak3 homolog (S. cerevisiae)
PFAAP5 21% 21% Immune? phosphonoformate immuno-associated protein 5
MCP 32% 26% Immune membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive 
antigen)
SMBP 26% 16% Membrane protein SM-11044 binding protein
MKLN1 21% 21% Ischemic tolerance/Cell adhesion? muskelin 1, intracellular mediator containing kelch motifs
ALDOA 26% 16% Metabolism (glycolysis) aldolase A, fructose-bisphosphate
IDI1 32% 26% Metabolism isopentenyl-diphosphate delta isomerase
CYB5-M 26% 16% Metabolism cytochrome b5 outer mitochondrial membrane precursor
GLO1 37% 21% Metalloglutathione (GSH) 
transferase
glyoxalase I
EIF3S6 21% 16% Translation eukaryotic translation initiation factor 3, subunit 6 48kDa
EIF1AX 16% 21% Translation eukaryotic translation initiation factor 1A
PCBP2 16% 16% Translation poly(rC) binding protein 2 (hnRNPE2)
HNRPA2B1 32% 21% Cell proliferation? heterogeneous nuclear ribonucleoprotein A2/B1
CDK6 16% 16% Cell-cycle cyclin-dependent kinase 6
CCNE2 16% 16% Cell-cycle G1/S-specific cyclin E2
PUM2 26% 21% Meiosis/RNA-binding pumilio homolog 2 (Drosophila)
TRA2A 16% 26% RNA-binding/? transformer-2 alpha (putative MAPK activating protein PM24)
ATXN2 16% 21% ? (but has RNA motif) ataxin 2
GTF2IP1 21% 26% Pseudogene general transcription factor II, i, pseudogene 1
H41 53% 26% ? hypothetical protein
C19orf13 26% 37% ? family with sequence similarity 61, member A (FAM61A)
CNIH 26% 26% ? cornichon homolog (TGAM77)
LOC400986 26% 26% ? protein immuno-reactive with anti-PTH polyclonal antibodies (HEM1)
ANKRD17 21% 21% ? ankyrin repeat domain 17 (breast cancer antigen NY-BR-16)
RHOBTB3 16% 16% ? (GTPase) Rho-related BTB domain containing 3
? - Unknown or unidentified gene product function
90 genes were identified to be both coexpressed with p68 and p72, and are arranged by function. For clarity all coexpressed gene products with a 
30% or greater coexpression frequency correlation for either p68 or p72 are in bold.
Table 1: Frequency overlap between p68 and p72 coexpressed genes. (Continued)
p72 (i.e. p72 was a positive for p68 and vice-versa), again
consistent with their interaction within the same path-
ways.
The next most abundant function of p68 and p72
appeared to be in transcription (Figure 2B), once more
consistent with previous reports. This is especially inter-
esting given that p68 and p72 were previously shown to
act as coactivators for the nuclear receptor estrogen recep-
tor α (ERα) transcription factor, and we have identified X-
box binding protein 1 (XBP1), associated with the ERα
pathway. We have also identified 2 other nuclear receptor
pathway proteins, the thyroid hormone receptor associ-
ated protein 2 (THRAP2) and the retinoic acid receptor-
related orphan receptor α (RORA) transcription factor.
RNA Helicase A(Dhx9) coexpresses and interacts with p68 
and p72
A further interesting transcription-associated gene identi-
fied was RNA helicase A (DHX9), a member of a similar
protein family to p68 and p72, all of which have been
shown to interact with p300/CBP coactivators[6,11-13].
The frequency for both p68 and p72 were observed to be
high for RNA helicase A (almost 50% of multi-arrays for
p68, and over 30% for p72).
For this reason a similar coexpression analysis was sepa-
rately performed for DHX9. Surprisingly, not only were
p68 and p72 reciprocally coregulated with DHX9, but
over 50% of the p68:p72 overlapped positives were also
coexpressed with DHX9 (47 out of 90 – see Additional fileBMC Genomics 2007, 8:419 http://www.biomedcentral.com/1471-2164/8/419
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2). This was powerful evidence linking Dhx9, p68 and
p72 to similar pathways.
As this overlap was so high it was possible that p68 and
p72 were functioning in the same complex as Dhx9. This
was tested experimentally in HEK293 cells. With immu-
noprecipitation of either transiently transfected p68 or
p72 we observed a clear interaction with endogenous
Dhx9 (figure 3A). Further imunoprecipitations of endog-
enous p68 and p72 from lysate of mouse liver confirmed
the interaction with Dhx9 (figure 3B). This was performed
after incubation with RNaseA, indicating a protein:pro-
tein interaction (as p68/p72/Dhx9 can all bind RNA). In
the liver extract p68 and p72 also strongly immunoprecip-
itated a protein of 100 kDa, recognised by the Dhx9 anti-
body (figure 3B). It currently remains unclear if this is a
different isoform of Dhx9 or a cross-reacting protein.
Altogether, these data both supported the hypothesis of
p68/p72/Dhx9 existing within the same complex, and fur-
ther acted as strong evidence of the predictive capabilities
of the Oncomine™ analysis technique described here.
p68 and p72 interact directly with predicted pathway partner Dhx9 Figure 3
p68 and p72 interact directly with predicted pathway partner Dhx9. (A) Left panel shows myc immunoblot of inputs 
from transiently transfected myc-p68 or -p72, or vector alone. Right panel shows RNA helicase A (Dhx9) immunoblot of 
inputs and myc immunoprecipitations (IP). (B) Dhx9 immunoblot of endogenous IP of p68 and p72 from mouse liver lysate 
(RNase A pre-treated). * Indicates either a shorter Dhx9 isoform or a cross-reacting (but immuno-precipitating) protein.
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Other coexpressed genes of p68 and p72
Interestingly, there were 4 overlapped hits in the ubiquitin
pathway (and one proteasome) which may be related to
the observation that p68 is highly ubiquitinated in colon
cancers[14]. p68 was also recently shown to be SUMO
modified, specifically SUMO-2 by PIAS1 ligase[15]. Here
we shown that PIAS1 is coexpressed with p68/p72, and
SUMO-2 is coexpressed with p68.
p68/p72 have also recently been shown to interact in a
complex with ILF3, hnRNPU, and hnRNPH1 for micro-
RNA processing[16]. Here, these gene products are also
shown to be highly coexpressed with p68 and p72, sup-
porting their role in the same complex/pathway (further-
more DDX3X is identified here with p68 and is also part
of this microRNA processing complex).
In a separate study a group of proteins were identified in
an mRNP complex with p68 and are here shown to be
coexpressed with p68/p72 (SFRS5,  NFAR/ILF3,
HNRNPA2/B1, HNRPU, PNN, TRA2A, DDX3X) [17].
A new role for p68 and p72, suggested by our meta-anal-
ysis, might be in nuclear transport, given that a member of
nuclear pore complex (Nup133) as well as nuclear import
(transportin1) and export (exportin1) genes were identi-
fied as coexpressed genes.
Furthermore, coexpressed genes presented here are not
limited to nuclear processes given that several cytoskeletal
proteins are identified in the screening, implicating p68
and p72 in these processes (although probably indirectly
as p68 and p72 are predominantly nuclear, perhaps acting
via transcription or splicing). This is also true for endo-
plasmic reticulum (ER) or golgi proteins. Indeed, the
RAB6A trafficking protein had the highest frequency over-
lap for p68 (almost 70% overlap), while being one of the
lowest for p72 (16% overlap), possibly indicative of a
functional difference between both. The family member
RAB14 was also identified for both.
A further significant group of genes identified were
involved in signal transduction, and may provide a start
into analysis of regulation of p68 and p72 (although a
meta-analysis like this can identify frequency of coexpres-
sion, it is impossible to say which protein may be regulat-
ing another, or indeed if both are targets of another
protein).
Altogether the results of the overlapping coexpressed
genes not only reiterate previous studies with either p68/
p72 but predict new potential pathways in which p68/p72
may act.
Selected non-overlapping coexpressed genes of p68 and 
p72
While p68 and p72 may be highly similar and involved in
the same pathways, it remains likely that they are also
involved in subtly different pathways. For this reason a
similar ontology analysis was performed on genes that do
not overlap between p68 and p72. However, given the
extensive nature of the gene hits we selected all genes with
frequency overlap above 30%, as well as some genes of
interest from lower frequencies (Table 2).
For p68 the genes above 30% generally fell into the same
categories as previously, while there was only 1 gene iden-
tified for p72, with no obvious molecular function. Of-
course the selected genes below 30% were chosen based
on interest and common ontological groupings, and may
not be representative. However, we note that for p68 more
RAB family members are identified (RAB1A, RAB11B) as
well as more ER proteins, particularly protein folding
chaperones (Tapasin, Calnexin, Calreticulin).
With regard to transcription, p68 coexpressed with ELK3
and HDAC2 transcriptional repressors, while p72 coex-
pressed with CTBP1 and HDAC7 repressors. This might be
relevant given that p68 and p72 have been shown to act as
transcriptional repressors, hypothesised to have different
mechanisms of action as they act in a promoter-specific
manner[7]. However it has been shown that CTBP1
repressive function is antagonized by pinin[18], and here,
both p68 and p72 also coexpress with pinin (PNN)[17].
p68 has also been shown to be involved in p53 coactiva-
tion[4], and here we identify a coexpressed p53 coactiva-
tor hnRNPK[19] for p68/p72 and the p53-induced
protein 7 (LITAF), for p68. For other transcription roles
for p68 there were more nuclear receptor pathway pro-
teins including thyroid receptor interacting protein 8
(JMJD1C),THRAP1  (THRAP2  was identified above for
both p68 and p72), estrogen receptor binding protein
(ERBP), and the retinoic acid receptor alpha (RARA) tran-
scription factor. p72 coexpressed with the ER-alpha
repressor MTA1. We have also observed that p68 coex-
pressed gene ZNF9 is in the same pathway as p68/p72
coexpressed  MBNL1, implicated in myotonic dystro-
phy[20].
For p72 we note that NonO (p54nrb) has been shown to
interact with SFPQ/PSF[21] (SFPQ  identified as coex-
pressed for both p68 and p72). Furthermore EDD (a ubiq-
uitin E3 ligase), also identified here with p72, has been
shown in a complex with SFPQ[22]. Remarkably p68 has
also very recently been shown to interact in a complex
with NonO and SFPQ/PSF[23], again confirming the
validity of the technique described here.BMC Genomics 2007, 8:419 http://www.biomedcentral.com/1471-2164/8/419
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Table 2: p68 and p72 frequency analysis of non-overlapping hits (all over 30% and selected below 30%).
p68 selected genes with no p72 overlap
Gene % Overlap Function Gene Name
FXR1 42% RNA-binding/Unknown fragile X mental retardation, autosomal homolog 1
HNRPK 37% Transcription/Translation/Signaling heterogeneous nuclear ribonucleoprotein K
NAP1L1 32% Transcription nucleosome assembly protein 1-like 1
JMJD1C 32% Transcription jumonji domain containing protein 1C (Thyroid receptor interacting 
protein 8)
SFRS11 32% Splicing splicing factor, arginine/serine-rich 11
MAPRE1 37% Cytoskeleton microtubule-associated protein, RP/EB family, member 1
ACTG2 32% Cytoskeleton actin, gamma 2, smooth muscle, enteric
PTPN11 32% Signal Transduction protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 
1)
JAK1 32% Signal Transduction janus kinase 1 (a protein tyrosine kinase)
ARF3 32% Vesicular Trafficking ADP-ribosylation factor 3
ANXA7 32% ER-calcium mobilization annexin A7 (Annexin VII) (Synexin)
COX7A2L 32% Metabolism cytochrome c oxidase subunit VIIa polypeptide 2 like
C6orf55 32% Anti-metastatic protein protein C6orf55 (Dopamine responsive protein DRG-1) (My012 
protein)
LAPTM4A 32% compartmentalization of amphipathic solutes lysosomal-associated protein transmembrane 4 alpha
ZNF9 32% ? zinc finger protein 9 (a cellular retroviral nucleic acid binding protein)
TDE1 32% ? tumor differentially expressed 1
SYPL 32% ? synaptophysin-like 1
NUCKS 32% ? nuclear, casein kinase and cyclin-dependant kinase substrate
ELK3 26% Transcription ELK3, ETS-domain protein (SRF accessory protein 2)
THRAP1 21% Transcription thyroid hormone receptor associated protein 1
RBBP4 21% Transcription retinoblastoma binding protein 4 (chromatin assembly factor/CAF-1 p48 
subunit)
ERBP 21% Transcription estrogen receptor binding protein
RARA 16% Transcription retinoic acid receptor, alpha
HDAC2 16% Transcription histone deacetylase 2
SNRPB 26% Splicing small nuclear ribonucleoprotein polypeptides B and B1
TAPBP 26% ER chaperone/Protein folding TAP binding protein (tapasin)
CALR 21% ER chaperone/Protein folding calreticulin
CANX 16% ER Chaperone/Protein folding calnexin
RAB1A 26% ER-golgi Transport RAB1A, member RAS oncogene family
RAB11B 21% Membrane recycling RAB11B, member RAS oncogene family
UCHL1 21% Ubiquitin ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
PSMA2 21% Proteolysis proteasome (prosome, macropain) subunit, alpha type, 2
PRKWNK
1
21% Proteolysis proteasome (prosome, macropain) 26S subunit, non-ATPase, 1
SUMO2 16% SUMO pathway small ubiquitin-like modifier, 2
CDC42 21% Cell-cycle cell division cycle 42 (GTP binding protein, 25kDa)
CDC40 21% Cell-cycle cell division cycle 40 homolog (yeast) [pre-mRNA splicing factor 17]
CDC10 26% Cytokinesis? septin-7 (CDC10 protein homolog)
LITAF 26% p53-induced Apoptosis lipopolysaccharide-induced TNF factor (p53-induced protein 7)
EIF3S10 26% Translation eukaryotic translation initiation factor 3, subunit 10 theta, 150/170 kDa
p72 selected genes with no p68 overlap
Gene % Overlap Function Gene Name
TTC3 32% ? tetratricopeptide repeat domain 3
HMGN4 26% Transcription high mobility group nucleosomal binding domain 4
CTBP1 21% Transcription/corepressor C-terminal binding protein 1
MTA1 21% Transcription/ER-alpha repressor metastasis associated 1
HDAC7A 16% Transcription histone deacetylase 7A
NONO 16% Splicing/Transcription non-POU domain containing, octamer-binding (p54nrb)
SFRS3 16% Splicing splicing factor, arginine/serine-rich 3
MAP2K3 26% Signal Transduction mitogen-activated protein kinase kinase 3
ERBB3 16% Signal Transduction receptor protein-tyrosine kinase erbB-3
CSK 16% Signal Transduction c-src tyrosine kinase
CALM2 16% Signal Transduction calmodulin 2 (phosphorylase kinase, delta)
RPS6 21% Ribosome 40S ribosomal protein S6BMC Genomics 2007, 8:419 http://www.biomedcentral.com/1471-2164/8/419
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Discussion
The technique described here has proven useful in increas-
ing the stringency of Oncomine™ meta-analysis, and will
prove to be widely applicable. Generally individual gene
levels cannot be compared from one study to another, but
the strength of our analysis is an inter-study comparison
(meta-analysis) after an intra-study Oncomine™ analysis
(coexpression gene search).
While we still retain the strongest 400 coexpressed genes
from each multi-array, it becomes de-sorted when analyz-
ing for frequency over different studies. An example is
EDEM1 (involved in protein folding in the ER), which is
consistently one of the strongest correlated genes with
p72, while having only a 32% frequency overlap. The
same is true for p68 and Sp3 transcription factor with a
frequency overlap of 37%, and very highly coexpressed in
these individual studies. Conversely, the technique
described here is useful for comparison of coexpressed
genes which may not always have a high coexpression
coefficient, giving another advantage over analysis of sin-
gle studies.
An interesting exception is RAB6A with p68 which has
both the highest frequency overlap with p68 (68%) and is
almost always within the first 100 genes coexpressed with
p68 in individual multi-array studies. A further exception
is RNA helicase A (DHX9) which again has a high fre-
quency of overlap with p68 (47%) and usually is within
the first 50 coexpressed genes with p68. We have also
shown here for the first time an interaction by immuno-
precipitation of p68 (and also p72), with Dhx9.
Furthermore, the technique described here is most useful
in clustering specific genes involved in pathways when
meta-analysis hits from known interacting proteins can be
overlapped. We observed with our example of p68 and
p72 that the overlapping hits mainly clustered into the
classes of ontology in which p68/p72 had already been
reported, namely splicing and transcription, further acting
as validation for this type of analysis.
While some new proposed pathways for p68/p72 cannot
be through direct action (e.g. cytoskeletal remodelling or
ER-protein folding) it remains possible that p68/p72 are
involved in these pathways indirectly via splicing/tran-
scription/controlling nuclear shuttling. We were encour-
aged by the fact that p68 and/or p72 coexpressed with
previously published interacting proteins such as one-
another, ILF3, hnRNPH1, hnRNPU, hnRNPA2/B1, SFRS5,
Ddx3X, PIAS1, SUMO2, pinin, NonO and SFPQ and were
further encouraged by observation of coexpression with
members of pathways in which they were previously
shown to act, such as estrogen receptor pathway (XBP1,
MTA1,  ERBP,  DDX5,  DDX17), ubiquitin pathway
(USPX9, UBE2J1, UBE3A, BIRC6, UCHL1, EDD), transla-
tion (EIF3S6, EIF1A, EIF3S10, PABPC1, EIF5), and tran-
scriptional repression (HDAC2,  HDAC7A,  PNN,  ELK3,
CTBP1, MTA1).
There also seems to be a more general role for p68 and
p72 in nuclear receptor transcription pathways than first
assumed (ERα pathway as above), for example JMJD1C,
THRAP1, THRAP2, RARA, RORA, all coexpress with p68
and/or p72.
While it is clear that we have obtained a highly stringent
list of potential pathway partners of p68 and p72, with
regard to separable functions (i.e. non-overlapping genes
of p68 and p72) we cannot say with confidence as genes
generally clustered into the same pathways as for the over-
lapping list. This may be due to a high false-negative rate
of this technique as we have used several levels of strin-
gency, and will most likely exclude many true pathway
partners of p68 and p72. However, this cost is offset by
high quality results using our rigorous analysis.
Conclusion
It is apparent that we have increased the scope of the
Oncomine™ database, by utilising frequency of coexpres-
sion (meta-analysis) over different multi-array studies to
predict pathway partners of searched proteins. With
regard to the p68 and p72 RNA helicases we have identi-
RPS15A 21% Ribosome 40S ribosomal protein S15a
MRPS6 26% Mitochondrial Ribosome Protein mitochondrial ribosomal protein S6
PABPC1 26% Translation poly(A) binding protein, cytoplasmic 1
EIF5 21% Translation eukaryotic translation initiation factor 5
EDD 26% ubiquitin E3 Ligase ubiquitin--protein ligase EDD
ARPC3 26% Cytoskeleton actin related protein 2/3 complex, subunit 3,21 kDa
WSB1 21% ? WD repeat and SOCS box-containing 1
GARNL1 21% ? GTPase activating RANGAP domain-like 1
?-Genes with unknown function. Genes with > 30% frequency overlap are in bold.
All coexpressed but non-overlapping gene products for p68 and p72 over 30% frequency are shown (and are in bold). Selected coexpressed gene 
products below 30% are shown and were chosen based on interest and common ontology groups.
Table 2: p68 and p72 frequency analysis of non-overlapping hits (all over 30% and selected below 30%). (Continued)BMC Genomics 2007, 8:419 http://www.biomedcentral.com/1471-2164/8/419
Page 10 of 11
(page number not for citation purposes)
fied a non-exhaustive list of gene products that are likely
to be present in various pathways in which p68 and/or
p72 act, both corroborating previous studies and making
novel predictions. For one of these, RNA helicase
A(Dhx9), we have shown there is a direct interaction with
p68 and p72. Future experimental studies using this list as
a reference point will reveal the validity of this technique.
Methods
Oncomine analysis
The following procedure was undertaken for meta-analy-
sis (figure 1B):
(1) Oncomine™ expression correlations were searched for
p68 (DDX5) or p72(DDX17). (2) 19 different mult-arrays
were chosen and the first 400 correlated genes within each
multi-array were compared using Microsoft Excel, (sepa-
rately for p68 and p72). Importantly, repetitive genes
were then removed within each study, leaving only 1 rep-
resentative per multi-array study. When a coregulated
gene appeared in more than 3 multi-array experiments it
was accepted as significant (3 = 16% frequency of the 19).
These genes were taken as more significant than analysis
of a single Oncomine™ output. Furthermore, given that
the user cannot choose which multi-array will be given by
Oncomine™ there was no attempt to specifiy different tis-
sue types or cancer types. This had the advantage of giving
a more generalised result of which pathways the proteins
may be involved in, which was preferred for an initial
study such as that performed here. (3) These sorted lists of
coregulated genes given for p68 and p72 were compared
for overlapping genes which added another level of strin-
gency, and greatly increased the significance of the results.
The genes listed were then investigated for ontology, and
full gene/gene-product names, using a combination of
Pubmed searches[24], Fatigo[25], and Genecards[26].
Cell culture, transfection, immunoprecipitation and 
western blot
HEK293 cells were transfected with either pSG5-myc,
pSG5-myc-p68, pSG5-myc-p72 (plasmids were a gift from
Frances Fuller-Pace, Dundee, UK), using FuGENE 6
(Roche). 48 h post-transfection cells were harvested on ice
in buffer B (150 mM KCl, 0.1% NP-40, 20 mM Tris-HCl
pH8.0, 5 mM MgCl2, 10% glycerol, 5 mM NaF, 1× Roche
complete protease inhibitor cocktail). 600 μg of total cell
extract was incubated with 5 μg 9E10 anti-myc mono-
clonal antibody, and protein G sepharose (GE Health-
care), rotating at 4°C for 2 h. Pellet was washed 3× in
buffer B, boiled in protein loading buffer that was then
run on an SDS-PAGE gel, transferred to pvdf and immu-
noblotted overnight at 4°C for Dhx9 (Bethyl Laborato-
ries) or myc.
For endogenous co-immunoprecipitation liver was
extracted from a 3 mth old male mouse and homogenised
in buffer B (Brinkmann polytron). Lysis was allowed to
happen, rotating at 4°C for 30 min. Sample was then cen-
trifuged to remove debris and further incubated with RNa-
seA, rotating at 4°C for 30 additional minutes, while
preclearing lysate with protein G sepharose. 2 mg of this
lysate was used with 3 μg of either p68 or p72 antibodies
(Bethyl Laboratories) per immunoprecipitation, which
were performed as above.
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